Corporate News Releases

ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper
ZyVersa Therapeutics and University of Miami Awarded a Grant from The Michael J. Fox Foundation to Determine if Inhibition of Microglial Inflammasome Activation with IC 100 Blocks Neuroinflammation Driving Parkinson's Disease Pathology
ZyVersa Therapeutics to Become a Publicly Traded Biopharma Company via Merger with Larkspur Health Acquisition Corp.
ZyVersa Therapeutics Sponsors American Diabetes Association Thought Leadership Video on Podocyte Lipotoxicity, a Cause of Diabetic Kidney Disease and Its Progression
ZyVersa Therapeutics' CCO, Karen A. Cashmere, Invited Speaker at Inflammasome Therapeutics Summit 2021
ZyVersa Therapeutics' CEO, Stephen C. Glover Invited Panel Member at Inflammasome Therapeutics Summit 2021
ZyVersa Therapeutics' CEO, Stephen C. Glover Invited Speaker at the H.C. Wainwright 23rd Annual Global Investment Conference, September 13-15, 2021
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at BTIG's Virtual Biotechnology Conference 2021
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at 2nd Annual LifeSci Partners' Virtual Private Company Summer Symposium July 21-23, 2021
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the H.C. Wainwright Global Life Sciences Conference Being Held Virtually March 9-10, 2021